. Author manuscript; available in PMC: 2014 Feb 26.

Published in final edited form as: Sci Transl Med. 2012 Nov 28;4(162):162ra155. doi: 10.1126/scitranslmed.3004327

Table 1.

Baseline characteristics of patients with Becker muscular dystrophy

	Exon Deletion	Age, at study, years	Age at onset of symptoms, years	Age at loss of ability to run, years	Maximum voluntary contraction (grip strength)		CK level, IU/L	Frequency of wheelchair/scooter use	Medications
	Exon Deletion	Age, at study, years	Age at onset of symptoms, years	Age at loss of ability to run, years	right arm, kg	left arm, kg	CK level, IU/L	Frequency of wheelchair/scooter use	Medications
P1	45–48	32	5	18	32	22	1883	never	none
P2	45–48	33	5	22	23	29	1247	never	none
P3	45–48	42	30	30	42	39	719	never	none
P4	45–55	38	12	26	29	23	2006	never	none
P5	45–48	42	28	32	29	33	1453	rarely	none
P6	48–49	38	25	27	35	33	2058	never	none
P7	67	50	32	38	36	42	2247	rarely	oxybutynin
P8	20–29	30	12	15	13	10	3745	never	deflazacort
P9	14–44	50	33	35	21	17	707	never	none
P10	3–7	19	6	8	13	12	2448	often	none

P, patient; CK, creatine kinase